News

Innovative Findings from TScan Therapeutics at ACR Convergence

Innovative Findings from TScan Therapeutics at ACR Convergence

TScan Therapeutics Makes Waves at ACR Convergence 2025

WALTHAM, Mass. – TScan Therapeutics, Inc. (NASDAQ: TCRX), a cutting-edge biotechnology company dedicated to the development of T cell receptor-engineered T cell (TCR-T) therapies, is thrilled to announce their participation at the prestigious American College of Rheumatology (ACR) Convergence 2025. This event takes place from October 24th to 29th in Chicago, showcasing the latest innovations in rheumatology.

Presenting Innovative Research

During the conference, TScan will be presenting two pivotal abstracts focusing on their research related to T cell-driven autoimmune disorders. This marks a significant milestone as they extend their focus beyond oncology into autoimmunity through their proprietary TargetScan technology.

Innovative Oral Presentation

One of the highlights is the oral presentation titled "TargetScan Platform Identifies Targets of CD8+ T cells in Ankylosing Spondylitis and Birdshot Uveitis". This session promises to illuminate the shared T-cell targets identified in Ankylosing Spondylitis (AS), a disease that has historically posed challenges in terms of understanding therapeutic targets.

Details of the Oral Presentation

Authors: Adam Weinheimer, Olivia Pryor, Catalina Burbano and others.
Abstract Number: 0888
Session Name: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Session Date/Time: Monday, October 27; 10:00 - 11:30 a.m. Central Time
Presentation Time: 10:45 - 11:00 a.m. Central Time
Location: Poster Hall

Poster Presentation Insights

TScan will also unveil a poster presentation titled "Identification of Novel HLA Class II–Restricted Autoantigens in Scleroderma and Ulcerative Colitis Using TargetScan". This work reinforces their commitment to leveraging technology to drive research in autoimmune disorders.

Details of the Poster Presentation

Authors: Olivia Pryor, Catalina Burbano, Nathaniel Bagge, Rutuja Kulkarni and others.
Abstract Number: 0997
Session Name: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster
Session Date/Time: Monday, October 27; 10:30 a.m. - 12:30 p.m. Central Time
Location: Poster Hall

TScan's Commitment to Innovation

TScan aims to address the complexities of autoimmune diseases. The insights gained from these studies highlight their ongoing commitment to enhancing therapeutic strategies using their unique TargetScan approach. Gavin MacBeath, Ph.D., Chief Executive Officer, emphasizes the excitement surrounding the initial findings, particularly in locating significant T-cell targets in AS. The advancements in this research could shape the future of drug development in autoimmune conditions.

About TScan Therapeutics

Founded to innovate the realm of T cell therapies, TScan Therapeutics focuses on creating TCR-T therapies for patients suffering from cancer. With two essential programs currently active—ALLOHA™ for hematologic malignancies and PLEXI-T™, aimed at solid tumors—they are moving the field forward. Their ImmunoBank serves as a repository of therapeutic TCRs, which enables them to develop a variety of personalized treatment options.

Contact Information

For further information, reach out to:
Heather Savelle
VP, Investor Relations
TScan Therapeutics, Inc.
Phone: 857-399-9840
hsavelle@tscan.com

Frequently Asked Questions

What is TScan Therapeutics primarily focused on?

TScan Therapeutics focuses on developing T cell receptor-engineered T cell therapies for cancer and autoimmune disorders.

Where will TScan be presenting their findings?

The presentations will take place at the ACR Convergence 2025 in Chicago, scheduled for October.

What are the main topics of TScan's presentations?

TScan will discuss their findings related to Ankylosing Spondylitis and autoantigens in Scleroderma and Ulcerative Colitis.

What technology does TScan utilize for their research?

TScan utilizes their proprietary TargetScan technology to identify T-cell targets.

How can I learn more about TScan's progress?

Interested individuals may contact TScan’s investor relations or visit their official website for updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 170

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
NatGold Pulling NATG From MEXC Amid Security Concerns

Updated Category News Views 536

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Continue Reading
Boston STEM Expo Sparks Young Minds in Engineering

Updated Category News Views 243

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Continue Reading
Historic Records Set at 2026 CNO Monumental Marathon

Updated Category News Views 421

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 547

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 282

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 253

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 505

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 601

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 421

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading

Top 5 Most Recently Viewed Articles

H.I.G. Realty Forms Innovative Partnership to Foster Growth

Updated Category News Views 271

H.I.G. Realty Collaborates with Queen Mary BioEnterprises H.I.G. Capital, a prominent global alternative investment firm with an impressive $67 billion in capital under management, has exciting news to share. They have entered a strategic partnership with Queen Mary BioEnterprises Innovation Centre, located in the bustling area of Whitechapel, London. This collaboration...

Continue Reading
Hycroft Mines Q2 Shows Stability and Expansion Plans

Updated Category News Views 28

Riding High with a Safety Record and Cash Reserves Hycroft Mining Holding Corporation isn't just treading water—they're swimming strong, closing out Q2 of 2026 with zero injuries and a whopping $220.5 million in the bank. No debt, zero accidents, and 1.4 million work hours without an incident—those are numbers you don't just stumble upon. This is a sign of a company...

Continue Reading
Exciting Collaboration Between Financial Associations for 2026

Updated Category News Views 235

Exciting Collaboration Between Financial Associations for 2026 Financial Executives International (FEI) and the Media Financial Management Association (MFM) have made a significant announcement about their 2026 Annual Conference. This event is set to be a landmark occasion as they will co-locate and co-brand the conference, bringing in financial leaders from across...

Continue Reading
Breakthrough in Gene-Editing Therapy Revolutionizes Hyperlipidemia Treatment

Updated Category News Views 279

Revolutionary Gene-Editing Therapy for Hyperlipidemia Unveiled CorrectSequence Therapeutics' CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy In a groundbreaking announcement, CorrectSequence Therapeutics Co., Ltd. has reported a notable milestone in the medical field. The completion of dosing for the first...

Continue Reading
Socket Mobile's CaptureSDK 2.0 Revolutionizes Data Capture Solutions

Updated Category News Views 124

Socket Mobile Launches CaptureSDK 2.0 for Enhanced Data Capture Socket Mobile, Inc. (NASDAQ: SCKT), a prominent player in the data capture industry, has made a significant leap forward with the introduction of CaptureSDK 2.0. This robust software solution sets the stage for a new generation of efficient and cost-effective barcode scanners that promise to benefit both...

Continue Reading